|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0022341,
umls-concept:C0205210,
umls-concept:C0246415,
umls-concept:C0282460,
umls-concept:C0457152,
umls-concept:C0684249,
umls-concept:C1274034,
umls-concept:C1274040,
umls-concept:C1518578,
umls-concept:C2347669
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2009-2-23
|
|
pubmed:abstractText |
Preoperative chemotherapy is a promising strategy in patients with early-stage resectable non-small-cell lung cancer (NSCLC); optimal chemotherapy remains unclear. Clinical (c-) stage IB/II NSCLC patients were randomised to receive either two cycles of docetaxel (D)-cisplatin (P) combination chemotherapy (D 60 mg m(-2) and P 80 mg m(-2) on day 1) every 3-4 weeks or three cycles of D monotherapy (70 mg m(-2)) every 3weeks. Thoracotomy was performed 4-5 weeks (DP) or 3-4 weeks (D) after chemotherapy. The primary end point was 1-year disease-free survival (DFS). From October 2002 to November 2003, 80 patients were randomised. Chemotherapy toxicities were mainly haematologic and well tolerated. There were two early postoperative deaths with DP (one intraoperative bleeding and one empyema). Pathologic complete response was observed in two DP patients. Docetaxel-cisplatin was superior to D in terms of response rate (45 vs 15%) and complete resection rate (95 vs 87%). Both DFS and overall survival were better in DP. Disease-free survival at 1, 2 and 4 years were 78, 65 and 57% with DP, and were 62, 44 and 36% with D, respectively. Preoperative DP was associated with encouraging resection rate and DFS data, and phase III trials for c-stage IB/II NSCLC are warranted.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-10655437,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-10694600,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-11773176,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-12445742,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-12488303,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-12781072,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-12815135,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-12837811,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-14722033,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-14736927,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-15226327,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-15280345,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-15337041,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-15886314,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-15972865,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-16000605,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-16014441,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-16061304,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-16622435,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-16945766,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-4075313,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-7911159,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-7911160,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-8043059,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-8158698,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-8622084,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-9187198,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18728643-9586914
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
pubmed-author:AsamuraHH,
pubmed-author:IchinoseYY,
pubmed-author:JCOG Lung Cancer Surgical Study Group,
pubmed-author:KatzEE,
pubmed-author:KoikeTT,
pubmed-author:KunitohHH,
pubmed-author:MitsudomiTT,
pubmed-author:NagaiKK,
pubmed-author:NakagawaKK,
pubmed-author:OkadaMM,
pubmed-author:SaijoNN,
pubmed-author:ShibataTT,
pubmed-author:TadaHH,
pubmed-author:TsuboiMM
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
16
|
|
pubmed:volume |
99
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
852-7
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18728643-Adenocarcinoma,
pubmed-meshheading:18728643-Adult,
pubmed-meshheading:18728643-Aged,
pubmed-meshheading:18728643-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18728643-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:18728643-Carcinoma, Squamous Cell,
pubmed-meshheading:18728643-Cisplatin,
pubmed-meshheading:18728643-Disease-Free Survival,
pubmed-meshheading:18728643-Female,
pubmed-meshheading:18728643-Humans,
pubmed-meshheading:18728643-Japan,
pubmed-meshheading:18728643-Lung Neoplasms,
pubmed-meshheading:18728643-Male,
pubmed-meshheading:18728643-Middle Aged,
pubmed-meshheading:18728643-Neoplasm Staging,
pubmed-meshheading:18728643-Preoperative Care,
pubmed-meshheading:18728643-Survival Rate,
pubmed-meshheading:18728643-Taxoids,
pubmed-meshheading:18728643-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
A randomised phase II trial of preoperative chemotherapy of cisplatin-docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer results of a Japan Clinical Oncology Group trial (JCOG 0204).
|
|
pubmed:affiliation |
Department of Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. hkkunito@ncc.go.jp
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
